title: An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib.
abstract: Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%-75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year.
authors.affiliation: Department of Respiration Medicine, Municipal Hospital, Qingdao, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Respiration Medicine, Municipal Hospital, Qingdao, People's Republic of China.
authors.forename: Huaping
authors.initials: H
authors.lastname: Tang
authors.affiliation: Department of Respiration Medicine, Municipal Hospital, Qingdao, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Respiration Medicine, Municipal Hospital, Qingdao, People's Republic of China.
authors.forename: Meng
authors.initials: M
authors.lastname: Li
keywords: EGFR; non-small cell lung cancer; tyrosine kinase inhibitor